Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Leritrelvir
reduces riskIncreased
risk →
reduces riskIncreased
risk →
Leritrelvir for COVID-19
3
studies with
>2,000
patients
Significantly lower risk for recovery and viral clearance.
3 studies from 3 independent teams (all from the same country) show significant
benefit.
COVID-19 Leritrelvir studies · November 2026
|
Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Leritrelvir
reduces riskIncreased risk → |
| Leritrelvir reduces COVID-19 risk: real-time meta-analysis of 3 studies (Version 2) | ||
| Significantly lower risk is seen for recovery and viral clearance. 3 studies from 3 independent teams (all from the same country) show significant benefit. Meta-analysis using the most serious outcome reported shows 30% [10‑46%.. | ||
Oct 31 |
et al., Journal of Thoracic Disease, doi:10.21037/jtd-2026-2569 | Effects of leritrelvir for adults with mild-to-moderate coronavirus disease 2019: A multicenter real-world study |
| 40% improved recovery (p<0.0001) and 18% improved viral clearance (p=0.04). Prospective study of 1,527 adults with mild-to-moderate COVID-19 showing faster sustained symptom resolution with leritrelvir. There were no deaths or progression to severe COVID-19. | ||
Jul 6 2024 |
et al., Quantitative Biology, doi:10.1002/qub2.60 | Assessing the inhibition efficacy of clinical drugs against the main proteases of SARS‐CoV‐2 variants and other coronaviruses |
| In vitro study showing that leritrelvir and GC376 remained effective against some nirmatrelvir- and ensitrelvir-resistant Mpro mutants. Leritrelvir showed better broad-spectrum activity against other pathogenic coronaviruses compared to e.. | ||
Mar 29 2024 |
et al., Nature Microbiology, doi:10.1038/s41564-024-01618-9 | Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir |
| In vitro and K18-hACE2 transgenic mouse study showing the preclinical efficacy of RAY1216, an inhibitor of the SARS-CoV-2 main protease (Mpro), against multiple SARS-CoV-2 variants. RAY1216 forms a covalent bond with the catalytic cystein.. | ||
Jan 31 2024 |
et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.102359 | Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial |
| 17% improved recovery (p=0.002) and 16% improved viral clearance (p=0.01). RCT 1,359 COVID-19 outpatients showing faster recovery with leritrelvir monotherapy (without ritonavir), 251 vs. 271 hours, and improved viral clearance. There were no significant differences in adverse events between groups. | ||
Sep 30 2023 |
et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.102189 | Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial |
| 35% faster recovery (p=0.04) and 21% improved viral clearance (p=0.01). RCT 60 hospitalized COVID-19 patients in China showing imporoved recovery and viral clearance with RAY1216, a 3CLpro inhibitor. | ||
